To introduce AI driven treatments in India
India, February 17, 2023
MindMaze, the Hinduja Group backed Unicorn, founded by a neuroscientist of Indian origin, Dr. Tej Tadi, is a global pioneer in the development of AI-driven neurotechnology. The company has today launched a first-of-its-kind, FDA-listed and CE-marked smart peripheral for patients with impairment in hand motor function Izar ®1 in the United States and European Union. It aims at introducing this path breaking treatments in India in association with Hospitals and Medical Centres that have adopted MindMaze technology platforms.
As of now, MindMaze technology is deployed at more than 130 top medical centres across the world. In India, it is deployed in more than a dozen institutions including the apex government hospital AIIMS, New Delhi. And Hinduja Hospital at Mumbai, through wholly owned subsidiary, MindMaze India.
In 2019, the largest contributors to the total neurological disorders in India were stroke (37·9%), headache disorders (17·5%), epilepsy (11·3%), cerebral palsy (5·7%), and encephalitis (5·3%) said a Lancet Global Health Survey.
This proprietary peripheral is a significant step forward in MindMaze’s efforts to deliver more effective patient care through combinations of smart peripherals with its growing portfolio of Digital Care and Digital Medicine solutions. Izar is part of a comprehensive omni site approach to the treatment and maintenance of neurological diseases, including Stroke, Parkinson’s disease, Alzheimer’s disease, and Traumatic Brain Injury (TBI), among others.
Our hands are vital for everyday life – from buttoning up a shirt, to eating, typing, or driving a car – hands are essential for personal and economic independence. Impaired hand function is one of the most common disabilities after stroke with paralysis of the hand and upper limb occurring in up to 87% of all stroke survivors. Not surprisingly, patients rate hand recovery as one of the most important factors associated with their improved quality of life and independence. Yet today hands remain incredibly challenging to treat under the current standard of care given the inherent limitations in time, resources, and technology. Izar allows clinics to finally address the unmet or underserved need of hand recovery through new in-clinic or remotely supervised self-training programs at home, increasing the dose and quality of training.
Izar is a hyper-sensitive controller built from the ground-up to train and assess both dexterity and strength, through capture of the fine grasp forces and wrist movements required to carry out activities of daily living. Izar can detect sub-newton level patient finger and hand forces, enabling treatment in the most impaired patient populations. This simple and highly portable controller is accompanied by proprietary and engaging gaming content that allows patients to self-train, either in-clinic, at bedside, or in the comfort of their home, dramatically enhancing and expanding training opportunities.
“It is very exciting to have a device for the hand that has the versatility of Izar. It can serve as a controller during reach-to-grasp movements, as a trainer of grip force gradation, and as an assessor of dexterity,” said Professor John Krakauer, M.D., Ph.D. and MindMaze’s Chief Medical Director. “The
device is also highly portable, so it can be used across the continuum of care, which is important as the upper limb, and the hand in particular, gets relatively neglected in neurorehabilitation.”
Leading global centers such as Shirley Ryan Ability Lab in the US, University College London in the United Kingdom, and The University of Auckland in New Zealand are already actively using Izar in pioneering clinical research. Izar was subjected to rigorous pre-launch testing across nine sites and delivered over 250 hours of active supervised and self-training therapy time in 250 patients, receiving unanimously positive feedback.
“With Izar I felt my hand again for the first time, I could even actively move it a bit and I saw that on the screen. It gave me a lot of hope,” said a Berit H., a patient from the P.A.N. Zentrum Centre in Germany. Julia Knape, a therapist from the same program added: “Our clients were actually surprised to see that they still had hand-finger functions. Through the visual feedback of even the smallest functions, they were more motivated for the therapy.”
Izar is available today in the US as well as European countries including France, Switzerland and Germany with content that enables training of dexterous grasp, pinch and grip. Future software content will unlock training content for wrist, bilateral movements, combination movements of the upper-limb and hand, as well as dexterity assessments for hand and wrist.
Founded in 2012, MindMaze is a global leader in brain technology and digital neurotherapeutic solutions for brain health and recovery. With a presence in over 15 countries, its mission is to accelerate the brain’s ability to recover, learn and adapt. The company has two core divisions – Healthcare and Labs – working collaboratively at the intersection of neuroscience, bio-sensing, engineering, mixed reality, and artificial intelligence. MindMaze Healthcare is advancing a universal platform for brain health with breakthrough solutions to some of the world’s most challenging problems in neurology, including stroke, Parkinson’s disease, and Alzheimer’s disease. MindMaze Labs, the company’s R&D innovation hub, is focused on the future of human computing – working across multiple industries to innovate and build the next generation of human-machine interfaces. The company has offices in Lausanne, Baltimore, London, Paris and Mumbai. For more information, please visit www.mindmaze.com.